glp-1 receptor agonist mechanism of action Mechanisms Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation GLP-1 Receptor Agonists in Solid

As 2024 drew to a close, Englands NICE finalised its guidance for Mounjaro, recommending its use in the primary care setting, for treating adults with a body mass index (BMI) 35 kg/m2 and at least one weight-related co-morbidity, alongside a reduced-calorie diet and increased exercise, with no restriction on treatment duration, equating to a total eligible population of 3.4 million patients [5]

Endocrinology 153 (2), 647658

Discuss carefully with your doctor

Safety, cost, and tolerability also influence which drug is better for a specific patient

Klebanoff: Medicaid programs are not required to cover drugs for weight loss, even if FDA-approved